PIK3CA mutation predicts resistance to breast cancer therapy

    Cancer Discovery
    |February 7, 2014
    PubMed

    Insights

    Women with PIK3CA mutations and HER2-positive, hormone receptor-positive breast cancer showed less benefit from neoadjuvant chemotherapy and HER2-targeted therapies. This finding impacts treatment strategies for this specific breast cancer subtype.

    Area of Science:

    • Oncology
    • Genetics

    Background:

    • HER2-positive, hormone receptor-positive breast cancer is a significant subtype.
    • PIK3CA mutations are common in breast cancer and can affect treatment response.

    Discussion:

    • This study investigated the impact of PIK3CA mutations on the efficacy of neoadjuvant chemotherapy and HER2-targeted therapies in HER2-positive, hormone receptor-positive breast cancer.
    • Results suggest that the presence of PIK3CA mutations may predict a diminished response to these standard treatment regimens.

    Key Insights:

    • Women with PIK3CA mutations in HER2-positive, hormone receptor-positive breast cancer demonstrated reduced benefit from neoadjuvant chemotherapy and HER2-targeted treatments.
    • The absence of PIK3CA mutations was associated with a greater likelihood of benefiting from these therapies.

    Outlook:

    • These findings highlight the importance of molecular profiling, specifically for PIK3CA mutations, in personalizing treatment strategies for HER2-positive breast cancer.
    • Further research may explore alternative or combination therapies for patients with PIK3CA mutations to improve outcomes.

    Related Concept Videos

    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    5.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.6K
    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    8.3K
    Cancer-Critical Genes I: Proto-oncogenes01:33

    Cancer-Critical Genes I: Proto-oncogenes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    9.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    2.6K
    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a...
    5.7K